Dare Bioscience 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Daré Bioscience reported approximately $48,000 in 3rd quarter 2026 revenue, compared with approximately $2,000 in the 3rd quarter of 2025; revenue primarily reflected research and development services and included initial FloraSync LF5 sales that began in July.
- Selling, general, and administrative expenses were approximately $2.6 million, compared with approximately $2.5 million in the 3rd quarter of 2025, while research and development expenses were approximately $0.3 million, compared with approximately $1.2 million in the prior-year period.
- Net loss for the quarter was approximately $3.2 million, compared with approximately $3.6 million in the 3rd quarter of 2025; cash and cash equivalents were approximately $11.5 million and working capital was approximately $3.2 million as of September 30th, 2026.
- FloraSync LF5 orders came from 27 states, the company received its first provider-office reorder, and early consumer feedback was a 4.9-star rating after approximately 25 reviews.
- Daré said 182 office-based providers had written DARE2PLAY prescriptions before dispensing began; prescriptions had been written across 48 states and the District of Columbia when office-based providers and telehealth were included.
- The company received a $1.5 million installment under its DARE-LARC I grant agreement, bringing total funding received under that agreement to approximately $43.3 million, and approximately $852,000 under its $10.7 million Gates Foundation grant for the ongoing Evaprene Phase 3 clinical trial, bringing total funding received under that agreement to approximately $9.9 million.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Hello, and welcome to the Daré Bioscience Third Quarter 2026 Financial Results and Corporate Update Conference Call and Webcast. As a brief reminder, all participants are currently in a listen-only mode. Following the presentation, there will be a question-and-answer session. Note that this webcast is being recorded at the company's request, and a replay will be made available on the company's website following the end of the event. Joining us today from Daré Bioscience are Sabrina Martucci Johnson, President and Chief Executive Officer, and MarDee Haring-Layton, Chief Accounting Officer. Ms. Haring-Layton, please proceed. Good afternoon and welcome.
Today, we will review our financial results, provide updates on our commercial products and clinical pipeline, and discuss the continued execution of our dual-path strategy, which involves commercializing proprietary formulations through 503B compounding while pursuing FDA approval and advancing select solutions as branded consumer health products that do not require a prescription. In all cases, our goal is to bring innovative women's health solutions to market as efficiently and as quickly as possible. I would like to remind you that today's discussion will include forward-looking statements within the meaning of federal securities laws, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements made during this call that are not statements of historical fact should be considered forward-looking statements.
Actual results or events could differ materially from those anticipated or implied by these statements due to known and unknown risks and uncertainties. You should not place undue reliance on forward-looking statements. Forward-looking statements are qualified in their entirety by the cautionary statements in the company's SEC filings, including our quarterly report on Form 10-Q for the quarter ended September 30, 2026, which was filed today, and our annual report on Form 10-K for the year ended December 31, 2025. Please note that the content of this call includes time-sensitive information that is current only as of today, November 16, 2026. Daré Bioscience undertakes no obligation to update any forward-looking statements to reflect new information or developments after this call, except as required by law.
I would also like to point out that when we use the term 503B compounding during this discussion, we are referring to compounding drug products by outsourcing facilities registered under Section 503B of the Federal Food, Drug, and Cosmetic Act using bulk drug substances on the FDA's interim Category 1 list. I would now like to turn the call over to Sabrina.
Thank you, Marty, and good afternoon, everyone, and thank you for joining us. At Daré, we have always believed that women's health deserves a business built around it, and that the health of women is an investment-grade category. That means developing products with a scientific foundation, addressing needs that have been overlooked, and creating practical ways for women to access those products. Today, you can see that strategy taking shape across our business. Flora Sync LF5 is in the market. Prescriptions for DARE to PLAY Sildenafil Cream are being written for patients across the country ahead of dispensing, and we are excited to be able to start reaching out to clinicians today to let them know that dispensing is planned to commence later this month. Two of our later-stage clinical programs are progressing toward data in 2027, and our grant-supported work is creating opportunities that we believe will extend the portfolio.
Our focus is on execution, building demand through trusted healthcare providers, preparing commercial supply, moving our studies forward, and securing an external support that helps us do more with our capital. For more than 10 years, Daré has been building towards this moment. We have the science, we have the commercial opportunities, and our job now is to turn them into a business that delivers for women and our shareholders. To start, I think it's important to highlight the progress we have made over just the past six months. We launched Flora Sync LF5, opening our first direct-to-consumer revenue channel. We added MyMenopauseRx as a specialized telehealth option for DARE to PLAY Sildenafil Cream. We initiated the DARE-HPV phase II study and announced a new U.S. patent expected to provide protection into at least 2039. We published new peer-reviewed Sildenafil Cream data in postmenopausal women and in men, expanding our evidence-based approach.
We secured additional non-dilutive support for DARE-LARC1 and DARE-PTB2, and our work on the DARE-IDDS drug delivery platform underlying the DARE-LARC1 technology has supported exploratory collaboration discussions around applications in obesity, diabetes, and other chronic conditions. Today, we've announced that DARE to PLAY Sildenafil Cream is en route to Medvantx, the central mail-order pharmacy handling prescription fulfillment to support dispensing planned to commence this month. I will discuss these areas in more detail, beginning with the continued national attention on women's health and why that matters to our development strategy, and of course, what it means that DARE to PLAY Sildenafil Cream is en route to Medvantx to start dispensing. The new executive order on women's health calls for a dedicated NIH Women's Health Division and a White House Women's Health Task Force.
The goals include better coordination of research and federal action, with an emphasis on translating discoveries into improved care for women throughout their lives. We view this as a continuation of an important national focus. Across successive administrations, women's health has been recognized as an area that requires attention, investment, and action. That continued attention may create additional non-dilutive funding and collaboration opportunities, and that has been central to our development strategy in helping us move programs forward while limiting shareholder dilution. Across our portfolio, we have been awarded more than $60 million from the Gates Foundation, $10 million through ARPA-H, and more than $5 million through NIH and NICHD-supported programs. In October, we received $1.5 million installment under our grant agreement for DARE-LARC1, bringing total funding received under that agreement to approximately $43.3 million.
We also received approximately $852,000 under our $10.7 million Gates Foundation grant for the ongoing Ovaprene phase III clinical trial and DARE-NHC, which is our non-hormonal contraceptive program, bringing total funding received under that agreement to approximately $9.9 million. This funding allows us to develop a broad portfolio while directing other capital toward commercial execution and priorities outside of these funded programs. Turning to our commercial activities, let me start with Flora Sync LF5, which is the first product in our DARE to RESTORE portfolio. Flora Sync LF5 is a non-hormonal probiotic vaginal capsule designed to support vaginal microbiome balance, moisture, and comfort. It is available without a prescription, and our first product sales began in July. What differentiates Flora Sync LF5 is the science behind it. Flora Sync LF5 was evaluated in a randomized clinical study involving 100 women, with results published in a peer-reviewed journal.
That level of product-specific clinical research is unusual in a category where consumers frequently encounter products with limited supporting evidence. We believe this creates meaningful commercial potential. There are an estimated 46 million sexually active women in the U.S. aged 15 to 49, and one survey found that approximately 65% of women aged 18 to 65 feel insecure about their vaginal scent. We are still in the early stages of commercialization, and our priority is disciplined execution. Our initial commercial focus has been clinician education and sampling. We are introducing the product to women's health providers, explaining the product-specific clinical research, and giving them an opportunity to become familiar with it. We are also beginning to receive orders from practices that want to make the product available for purchase in their offices. That creates a direct connection between a provider's recommendation and a woman's ability to access the product.
Our objective is to turn those initial introductions into continued recommendations, office purchases, and repeat consumer demand. That is the commercial foundation we are building, and we are seeing evidence that this approach is working. While the revenue in the first month was not material, in the early stages of launch, we are looking at other indicators that we believe can be predictive of future performance. Specifically, we are looking at geographic reach. Flora Sync LF5 orders have come from 27 states. We are looking at provider traction, and we have received our first provider office reorder. Customers are also telling us that they purchased Flora Sync LF5 after receiving a recommendation or a sample from their healthcare provider. These are the connections our commercial strategy is designed to create: clinicians introducing the product, women making a purchase, and practices returning to order again.
Early consumer feedback has been very positive, with a 4.9-star review rating after the initial approximately 25 reviews. As we plan for 2027, we are also evaluating additional retail channels for product discovery and reorder so that women may first hear about Flora Sync LF5 from their clinician or social media and then choose the purchasing channel that is most convenient for her. That includes working with Amazon. We were thrilled that Flora Sync LF5 was selected by Amazon for their new seller recruitment program, and we are looking forward to making the product available on Amazon in early 2027. We are also pleased to be expanding the DARE to RESTORE brand family to include Flora Renew and Flora Reset, a vulvar mask and cleanser, both anticipated in early 2027.
I am excited, no pun intended, to turn to DARE to PLAY Sildenafil Cream, our proprietary topical sildenafil cream formulation designed specifically for women, which we are bringing to market in collaboration with a 503B registered outsourcing facility. Product is en route today from the 503B outsourcing facility to Medvantx, which is the mail order pharmacy, and we expect prescription dispensing to begin in November. Over the last several months, our 503B facility partner has been preparing for this day, preparing to provide supply at commercial scale, and I want to spend a moment on what that means. DARE to PLAY Sildenafil Cream is not made at a compounding pharmacy one tube at a time on an individual prescription basis. We have been preparing for commercial-scale production at a registered outsourcing facility operating under pharmaceutical good manufacturing practice requirements.
That manufacturing process is an important part of being able to supply the product consistently at the scale that the demand requires. We know women and providers are waiting, so it is rewarding that we can start reaching out to them today to let them know that dispensing is planned to commence later this month. The underlying need remains substantial, with an estimated 20 million women in the United States alone experiencing symptoms of low or no sexual arousal. At a price of $99 per tube, which provides about 10 uses, the estimated addressable population of 20 million women represents a total market opportunity of approximately $2 billion. Even modest market penetration could create meaningful commercial value in an area with limited female-specific options. We are also continuing our dual-path strategy.
The 503B regulatory pathway provides a way to make the formulation available by prescription now, while we continue engaging with the FDA on the phase III development program and pursuing potential approval through the 505(b)(two) regulatory pathway. While we have been preparing for dispensing, our provider outreach has been translating into written prescriptions. 182 office-based providers, not including telehealth, have already written DARE to PLAY prescriptions before the product is even available. If we include both office-based providers and telehealth, prescriptions have been written across 48 states and the District of Columbia. Clinicians can also stock and dispense DARE to PLAY directly from their offices, and during the sexual health conference that just happened this past weekend, the first such order was received. What matters is that engagement is coming through both access channels. Office-based providers can introduce the product through an established clinical relationship.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
6 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
